One death was linked to chemotherapy used before the experimental treatment, according to the company. The announcement adds to scrutiny of a promising but increasingly complicated field of autoimmune research.
Artiva Bio-therapeutics is abandoning its experimental cell therapy for autoimmune diseases after reporting two patient deaths and finding that treatment benefits did not last long enough to justify continued development. The San Diego-based company announced October 27 that it would stop developing AlloNK, cancel a planned Phase 3 trial and cut approximately 94% of its workforce. investors.artivabio
The deaths raise urgent questions about safety, but the distinction between the cell therapy and the broader treatment regimen matters. According to Artiva, an investigator and an independent safety review assessed one patient’s fatal neurological complication as likely related to fludarabine, a chemotherapy drug administered before the cell therapy. A second patient died suddenly about two months after starting treatment; the investigator assessed that death as unrelated to any component of the regimen, although its cause remains undetermined. investors.artivabio
Artiva’s announcement comes amid other deaths reported in autoimmune cell therapy trials, intensifying debate over how to weigh the potential benefits of these experimental treatments against serious risks. Those events involve different products and clinical circumstances—not a single established explanation for what went wrong. statnews statnews biospace
What happened in the Artiva trial?
Artiva was studying AlloNK, also known as AB-101, in combination with rituximab for rheumatoid arthritis and other autoimmune diseases driven by B cells. The experimental treatment uses donor-derived natural killer, or NK, cells and is not genetically modified. investors.artivabio
In the company’s Phase 2a trial, one participant developed a fatal neurological condition called leukoencephalopathy after receiving study treatment. The protocol included cyclophosphamide and fludarabine as a preparatory regimen known as lymphodepletion. Artiva said the investigator and an independent safety review considered the event likely related to fludarabine-associated neurotoxicity. investors.artivabio
After Artiva reported the death, the U.S. Food and Drug Administration asked the company to pause enrollment and dosing in the Phase 2a study, according to the company’s announcement. Artiva also paused its planned Phase 3 enrollment and dosing.investors.artivabio
The second participant experienced sudden death approximately two months after beginning study treatment. Artiva said the investigator assessed the event as unrelated to AlloNK or any other component of the regimen. However, the company also stated that the cause of death had not been determined. investors.artivabio
That leaves an important limit on what can be concluded: the public disclosure describes investigators’ assessments, not a fully established explanation for both deaths. It would be inaccurate to say that AlloNK itself was shown to have caused them. It would also be inaccurate to describe both deaths as unrelated to the treatment process, because the first was assessed as likely linked to a drug used in that process. investors.artivabio
Why the chemotherapy component matters
The first death draws attention to a question that extends beyond Artiva’s product: how safe is the entire treatment regimen, including the medicines used to prepare patients for cell therapy?
In Artiva’s trial, fludarabine and cyclophosphamide were part of the protocol patients received before AlloNK. Even if investigators did not identify the NK cells themselves as the likely cause of the neurological death, the suspected complication arose from a component of the study treatment.investors.artivabio
Artiva acknowledged the broader significance of that finding. The company said it intends to publish additional details of the case because fludarabine-containing lymphodepletion regimens are widely used in cell therapy development.investors.artivabio
“We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families,” Artiva CEO Dr. Fred Aslan said in the announcement. investors.artivabio
The program also fell short on lasting benefit
The decision to stop development was not based on the deaths alone.
Artiva said updated findings continued to show deep B-cell depletion and clinical activity consistent with earlier results. But longer-term follow-up did not show the durability of clinical response the company believed was necessary to continue development. In other words, the treatment showed activity, but its benefits did not persist long enough to meet Artiva’s development threshold. investors.artivabio
The company said it weighed the overall risk-benefit profile, likely enrollment delays, and the development and potential commercial outlook before ending the program. No additional patients will receive AlloNK in ongoing studies, and the planned Phase 3 pivotal trial will not begin.investors.artivabio
That combination serious safety events and insufficiently durable benefit is central to understanding the shutdown. A treatment’s ability to change an immune-system marker is not, by itself, the same as demonstrating a lasting clinical benefit worth its risks. Artiva’s announcement explicitly distinguished its continued observation of B-cell depletion from its disappointment with the duration of patients’ responses. investors.artivabio
A broader field faces mounting scrutiny
Artiva’s disclosure follows other troubling developments in autoimmune cell therapy research.
On October 23, Bristol Myers Squibb reported a death in an early trial of an investigational CAR-T therapy for multiple sclerosis. According to STAT, the patient experienced motor symptoms that did not resolve with standard autoimmune treatments, subsequently received a potent immunosuppressant, and developed fatal septic pneumonia. Bristol Myers told STAT that complications treated before CAR-T therapy complicated efforts to determine the root cause. statnews
Separately, Novartis paused several autoimmune trials of its investigational CAR-T therapy rapcabtagene autoleucel, or rap-cel, after three patient deaths. BioSpace reported that the deaths involved a life-threatening hyperinflammatory syndrome known as immune effector cell-associated hemophagocytic lymphohistiocytosis–like syndrome, or IEC-HS. biospace
These cases should not be treated as interchangeable. Artiva’s AlloNK is a non-genetically modified NK-cell product, while the Bristol Myers and Novartis programs involve CAR-T therapies. The reported complications also differ: suspected chemotherapy-associated neurological toxicity, fatal infection in a medically complex case, and severe hyperinflammation. investors.artivabio statnews biospace
Together, however, the reports sharpen a shared question: what level of treatment-related risk is acceptable for people seeking relief from serious autoimmune disease, and how durable must the benefit be to justify that risk? STAT has identified that risk-benefit debate as a growing concern for the field. statnews
What remains unanswered
Artiva’s announcement does not identify the two patients’ specific autoimmune diagnoses, provide a confirmed cause for the second death, or present enough detailed outcome data to independently evaluate the full balance of benefit and harm. The disclosure also does not provide the treatment denominator needed to calculate a meaningful mortality rate from the two deaths. investors.artivabio
Additional transparency will therefore matter. Artiva has committed to continued safety monitoring and reporting as its studies close, working with the FDA, investigators and institutional review boards. It also plans to share more information about the suspected fludarabine-associated death in a scientific publication. investors.artivabio
For patients and families following this research, the immediate outcome is clear: AlloNK development has ended. The larger implications are still being worked out and depend on understanding not only what the experimental cells did, but what happened throughout the entire course of treatment. investors.artivabio